Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of…
<!-- Name:DistributionId Value:8784693 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
BNC210
Quarterly Activities and Cashflow Report
<!-- Name:DistributionId Value:8739323 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social…
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints…
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the…
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel,…
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American…
ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing…
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million
ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to…